Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Imprinting in Metabolic Diseases - Identifying Epigenetic Mechanisms in Human Gestational Diabetes Through Cell-free DNA - Part B (Epi_GDM_B)

12 november 2026 uppdaterad av: Martin Heni, University of Ulm

This clinical trial aims to investigate the development of and changes in fetal epigenetic signatures and how maternal metabolism influences these.

The metabolic profiles of the mother will be evaluated at three timepoints during pregnancy from a fasting blood sample and at another timepoints from an oral glucose tolerance test. Fetal epigenetic signatures can be identified by analyzing fetal cell-free DNA that circulates in the mother's bloodstream.

Studieöversikt

Status

Har inte rekryterat ännu

Detaljerad beskrivning

Maternal metabolism during pregnancy plays an important role in fetal development and may influence the establishment and development of epigenetic signatures in the fetus. Epigenetic modifications, such as DNA methylation, regulate gene expression and are involved in numerous developmental processes. Alterations in these epigenetic patterns during pregnancy may have long-term consequences for offspring health and susceptibility to metabolic diseases. In particular, maternal metabolic conditions, including gestational diabetes mellitus (GDM), may influence fetal epigenetic programming. However, the dynamic development of fetal epigenetic signatures throughout pregnancy and their relationship with maternal metabolic changes remain insufficiently understood.

Investigating the fetal epigenome during pregnancy has long been challenging due to the limited availability of fetal tissue and the risks associated with invasive sampling procedures. The discovery of fetal cell-free DNA (cfDNA) circulating in maternal blood provides a non-invasive opportunity to investigate fetal characteristics during pregnancy. Recent advances in cell-free DNA analysis have made it possible not only to detect fetal genetic information but also to characterize fetal epigenetic signatures.

The primary objective of this study is to investigate the development and changes in fetal epigenetic signatures throughout pregnancy and to assess how maternal metabolic profiles influence these signatures. In particular, the study aims to identify associations between maternal metabolic parameters and fetal epigenetic modifications and to explore potential changes in these associations over the course of pregnancy. Furthermore, the study seeks to identify fetal epigenetic signatures associated with [specific maternal metabolic conditions, e.g. gestational diabetes mellitus] and to explore their potential as biomarkers of maternal metabolic status and fetal development.

To address these objectives, maternal metabolic profiles will be assessed at three time points during pregnancy using fasting blood samples collected at 11+0-13+6, 19+0-24+0, and 28+0-34+0. Fetal health will be assessed via ultrasound measures at these timepoints. Maternal glucose metabolism will be characterized using an oral glucose tolerance test (OGTT) at 24+0-27+6. Fetal epigenetic signatures will be investigated by analyzing fetal cell-free DNA circulating in maternal blood samples collected at all four timepoints.

By combining longitudinal maternal metabolic assessments with the analysis of fetal epigenetic signatures, this study aims to provide new insights into the relationship between maternal metabolism and fetal epigenetic development during pregnancy. The findings may contribute to a better understanding of the mechanisms underlying fetal metabolic programming and the potential long-term consequences of altered maternal metabolism for offspring health.

Studietyp

Observationell

Inskrivning (Beräknad)

15

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Studieorter

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Kvinna

Testmetod

Icke-sannolikhetsprov

Studera befolkning

Participants will be recruited from public advertisements posted at Ulm University as well as through cooperations with local gynecologists.

Beskrivning

Inclusion Criteria:

  • Pregnant women from gestational week 13+0
  • No known underlying medical conditions i
  • No known underlying diseases
  • Understanding and voluntary signing of a consent form before study- related examinations

Exclusion Criteria:

  • Age < 18 years
  • Type 1 or type 2 diabetes mellitus
  • Pharmacological treatment affecting blood glucose levels (e.g., steroids, insulin)
  • Endocrine disorders (e.g., hyperthyroidism, polycystic ovary syndrome [PCOS])
  • Current depression or other psychiatric disorders
  • Eating disorders
  • Regular use of medication during pregnancy
  • Pre-existing cardiovascular disease
  • Drug and/or alcohol abuse
  • Estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73 m²
  • C-reactive protein > 10 mg/l
  • Transaminase elevation of 2 times the upper norm
  • No consent to be informed about incidentally discovered pathological findings
  • Any other (clinical) condition that would endanger participants safety or question scientific success according to the physicians opinion.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: FAMILY_BASED
  • Tidsperspektiv: PROSPECTIVE

Kohorter och interventioner

Grupp / Kohort
Intervention / Behandling
Pregnant women

Metabolic and epigenetic characterization

Maternal metabolic profiles will be assessed at three time points during pregnancy using fasting blood samples and at an additional time point using an oral glucose tolerance test (OGTT). Fetal epigenetic signatures will be investigated through the analysis of fetal cell-free DNA circulating in maternal blood. Fetal health will be assessed by ultrasound at the timepoints of the fasting blood samples No therapeutic intervention will be performed.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Epigenetic profiles of mothers and fetuses
Tidsram: Gestational weeks 13+0 - 34+0

Methylation pattern of CpG sites in fathers, mothers and fetuses assessed from blood samples from the father and the mother.

Genome-wide DNA methylation will be quantified as 5-methylcytosine (5mC) levels at CpG sites in maternal and paternal nuclear DNA from peripheral blood. Long-read sequencing will be used to detect genomic sequences and base modifications. Fetal DNA methylation will be assessed from fetal cell-free DNA isolated from maternal plasma using long-read sequencing. Allelic phasing will be applied to assign epigenetic modifications to parental origin. Deconvolution analysis will be used to subtract blood cell-derived epigenetic patterns and infer tissue-of-origin signals.

Gestational weeks 13+0 - 34+0
Changes in epigenetic profiles of mothers and fetuses during pregnancy
Tidsram: Gestational weeks 13+0 - 34+0

Changes in epigenetic profiles as determined in Primary Outcome 1 during pregnancy.

Gestational weeks 13+0 - 34+0

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Epigenetic signatures of gestational diabetes
Tidsram: Gestational weeks 13+0 - 34+0

Differentially methylated regions will be computed across parental genomic DNA and fetal cell-free DNA between women with and without gestational diabetes. Differentially methylated regions will be bioinformatically annotated to candidate genes and pathogenic pathways.

Gestational weeks 13+0 - 34+0
Correlation of epigenetic signatures and glycemia
Tidsram: Gestational weeks 13+0 - 34+0

Glucose level assessed from glucose measurements from fasting blood sample or oral glucose tolerance test.

Gestational weeks 13+0 - 34+0
Correlation of epigenetic signatures with weight gain
Tidsram: Gestational weeks 13+0 - 34+0

Correlation of changes in epigenetic signatures as assessed in primary outcome 2 with maternal weight gain.

Gestational weeks 13+0 - 34+0
Correlation of epigenetic signatures and insulin sensitivity
Tidsram: Gestational weeks 13+0 - 34+0

Insulin sensitivity assessed by Homeostasis Model Assessment of insulin resistance based on glucose and insulin measurements from fasting blood sample or oral glucose tolerance test.

Gestational weeks 13+0 - 34+0
Correlation of epigenetic signatures and insulin secretion
Tidsram: Gestational weeks 13+0 - 34+0

Insulin secretion assessed by Homeostasis Model Assessment of beta-cell function based on glucose and insulin measurements from fasting blood sample and oral glucose tolerance test.

Gestational weeks 13+0 - 34+0
Correlation of epigenetic signatures and lipids
Tidsram: Gestational weeks 13+0 - 34+0

Lipid profiles assessed from lipid measurements from fasting blood sample.

Gestational weeks 13+0 - 34+0
Correlation of of epigenetic signatures with anthropometric features of the fetus
Tidsram: Gestational weeks 13+0 - 34+0

Correlation of epigenetic signatures as assessed by primary outcome 1 with anthropometric features of the features assessed by ultrasound.

Gestational weeks 13+0 - 34+0

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 januari 2027

Primärt slutförande (Beräknad)

31 december 2028

Avslutad studie (Beräknad)

30 juni 2029

Studieregistreringsdatum

Först inskickad

12 november 2026

Först inskickad som uppfyllde QC-kriterierna

12 november 2026

Första postat (Faktisk)

18 november 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

18 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

12 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera